Amneal Pharmaceuticals (AMRX) Research & Development (2017 - 2026)

Amneal Pharmaceuticals' Research & Development history runs 10 years deep, the most recent figure standing at $38.4 million for Q1 2026.

• On a quarterly basis, Research & Development fell 4.14% year-over-year to $38.4 million in Q1 2026; TTM through Mar 2026 was $184.5 million, a 3.62% decrease from a year earlier, with the FY2025 full-year figure at $186.2 million, down 2.38% from the prior year.
• Research & Development climbed to $38.4 million in Q1 2026 per AMRX's latest filing, from $34.8 million in the prior quarter.
• Across five years, Research & Development topped out at $63.4 million in Q3 2025 and bottomed at $34.8 million in Q4 2025.
• The 5-year median for Research & Development is $41.9 million (2022), against an average of $45.6 million.
• Across the five-year window, Research & Development surged 47.67% in 2024 and sank 35.84% in 2025, its largest moves.
• Year by year, Research & Development stood at $41.9 million in 2022, then advanced by 9.97% to $46.1 million in 2023, then advanced by 17.75% to $54.3 million in 2024, then tumbled by 35.84% to $34.8 million in 2025, then rose by 10.24% to $38.4 million in 2026.
• Per Business Quant, the three latest AMRX Research & Development figures stand at $38.4 million (Q1 2026), $34.8 million (Q4 2025), and $63.4 million (Q3 2025).